AI GxP validation for regulated life sciences
CSA

Defending CSA in an Inspection: The Questions and the Evidence

The fear that stops teams adopting CSA is the audit. What inspectors actually ask when you have tested less, the evidence that answers them, and the record that makes a risk-based decision defensible.

Cybroscape Technologies5 min read

Key takeaway

The fear that stops teams adopting CSA is the audit. What inspectors actually ask when you have tested less, the evidence that answers them, and the record that makes a risk-based decision defensible.

Here's the honest reason CSA adoption stalls: nobody is afraid of the guidance, they're afraid of the moment an inspector says "show me why you only tested this much".

It's worth facing that question directly, because it has a good answer — provided you built the record while you were deciding, not afterwards. These are the questions that come up and the evidence that settles them.

The questions

"Why did you test this function this way?"

The answer is your risk assessment, and it needs to be a sentence, not a score: what could go wrong, how bad would it be, and would anyone notice before it mattered. A rating of "low" with no reasoning behind it is the weakest thing in any CSA package.

"Who decided that, and were they qualified?"

Named roles — process owner, QA, and someone who understands the system technically. A risk assessment authored by one person alone is the most common structural weakness. See roles and responsibilities.

"Show me an unscripted test."

They will pick one. You need the charter written beforehand, the trail of what was done, the findings, and who accepted them — covered in unscripted testing under CSA.

"You relied on the vendor here. What did you check?"

Your supplier assessment, what specifically you leveraged, and the rationale for considering it sufficient. "They are a large vendor" is not a rationale.

"What did you test harder because of this approach?"

This is the question that separates real CSA from reduced effort — and the one teams least expect. If everything got lighter, the assessment did no work.

The evidence that answers them

  • A risk assessment with written rationale per function, approved before testing.
  • A validation plan that states which testing method applies to which risk level, and why.
  • Traceability from requirement to the evidence that covers it — whatever form that evidence took.
  • Supplier assessment records for anything leveraged.
  • Test records that a stranger could follow, scripted or not.
  • Deviations raised during testing, investigated properly rather than closed quietly.

Notice that none of this is unusual. It is the same package, with the risk reasoning promoted from an annex to the centre.

How to sound credible

Lead with patient impact, not efficiency. "We concentrated testing where an error could affect product quality" lands very differently from "CSA let us reduce documentation". Both may be true; only one is the reason.

Don't claim CSA is a regulatory requirement. It is FDA guidance describing an approach. Saying "the FDA told us to test less" invites a correction you do not want.

Have a failure ready. Show a case where the approach found something and you acted on it. Evidence that testing works beats any explanation of method.

Be straight about limits. If an area was leveraged from a vendor and you did not independently test it, say so and explain the basis. Inspectors respond far better to a clearly stated, justified decision than to a vague implication of coverage.

For the preparation routine, see preparing for a GxP audit. For the approach itself, moving from CSV to CSA and GxP software.

Where to go next

Explore Cybroscape GxP Copilot for AI-native validation, Cybroscape TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.

Part of our guide to GxP software — categories, evaluation criteria and how the platforms compare.

High riskFailure could affect patient safety or product quality
Scripted testingWritten steps, expected results, an independent reviewer
Step-by-step results, screenshots and signatures
Medium riskFailure is noticed and contained
Unscripted testingExploratory or ad-hoc testing against the intended use
A record of what was tested, by whom, and the result
Low riskStandard function, supplier-tested
Supplier evidenceThe vendor’s own testing, assessed and accepted
The assessment and the reason it is enough
Computer Software Assurance in one picture: test effort follows the risk of each requirement. Based on FDA’s Computer Software Assurance guidance.
See it on your own systemBring a URS or a system. We run GxP Copilot against it live on the call.
csa auditgxp validationcsa inspectiondefend risk based validationcsa regulatory acceptancefda csa inspection questions
FAQ

Frequently Asked Questions

Prefer to talk first? Chat with us on WhatsApp or book a call with an expert.

What do inspectors ask about a CSA-based package?

Why each function was tested the way it was; who made that decision and whether they were qualified; to see a specific unscripted test; what you checked before leveraging vendor evidence; and — the one teams least expect — what you tested harder as a result of the approach.

What evidence do you need to defend CSA?

A risk assessment with written rationale per function, approved before testing; a validation plan mapping testing method to risk level; traceability from requirement to evidence; supplier assessment records for anything leveraged; test records a stranger could follow; and deviations raised during testing that were properly investigated.

How should you explain CSA to an inspector?

Lead with patient and product impact, not efficiency: 'we concentrated testing where an error could affect product quality' lands very differently from 'CSA let us reduce documentation'. Be straight about what was leveraged rather than implying coverage you do not have.

What is the weakest part of most CSA packages?

Risk ratings without reasoning. A score with no sentence explaining what could go wrong, how bad it would be and whether anyone would notice cannot be defended two years later when the author has left. A close second is an assessment authored by one function alone.

Should you show an inspector a test failure?

Yes. A case where the approach found something and you acted on it is stronger evidence that testing works than any explanation of methodology. A package with no findings at all invites the question of whether the testing was real.

Keep reading

All articles
CSAUnscripted Testing Under FDA CSA: Charter Examples, Evidence & What Inspectors ExpectWhat unscripted and exploratory testing mean under FDA's finalised Computer Software Assurance (CSA) guidance, copy-paste test charter examples, what evidence an inspector expects when there is no script, and how Cybroscape GxP Copilot automates it. · 6 min readRegulatoryDo You Need to Rename AI in Your SOPs and Validation Documents?The short answer is no. The longer answer covers where the new terminology will reach you anyway, how to write documents that survive a vocabulary change, and why a global find-and-replace is the wrong reflex. · 5 min readBest PracticesOutsourcing Validation: What to Keep In-House and What to Hand OverValidation capacity is hard to hire and uneven in demand, so most regulated companies outsource some of it. What transfers safely to a partner, what never should, and how to run the relationship so accountability stays where the regulator expects it. · 5 min readBest PracticesValidation Metrics That Actually Mean SomethingMost validation dashboards measure activity, not quality: documents produced, tests executed, days elapsed. The measures that tell you whether validation is working, and the ones that quietly reward the wrong behaviour. · 5 min readCSAHow to Move From CSV to CSA Without Restarting Your Quality SystemA practical transition from scripted CSV to Computer Software Assurance: what changes in your SOPs, what to pilot first, how to bring QA with you, and the mistakes that make CSA look like cutting corners. · 6 min readCSACSV vs CSA: what actually changed with FDA Computer Software AssuranceA plain-English guide to what CSA replaces, what it keeps, and how to actually shift your validation practice. · 3 min readCSARisk-based testing under CSA: how to actually reduce scripted-test effortThe per-requirement risk model that lets you defensibly cut scripted testing on non-critical requirements. · 6 min readValidationDecommissioning a GxP System: Retiring It Without Losing the RecordsSwitching a validated system off is a controlled activity, not an IT task. What has to happen before shutdown, how to keep records retrievable for their full retention period, and why half-retired systems are an inspection risk. · 5 min read

Bring a system. We'll show you the package.

Book a demo, or ask a validation lead a quick question on WhatsApp.

  • We reply within one business day
  • We run your URS live on the call
  • You get a clear plan for your system
Chat on WhatsApp

Book a demo

Four fields. The right specialist replies within one business day.

Your details stay private. We never share them.